CalciMedica, Inc.
CALCNASDAQ
Healthcare
Biotechnology
$0.58
-0.01(-1.9%)
52W $0.51 – $6.74
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs.
$9MMkt Cap
—Rev TTM
-$31.0KNI TTM
-328.3xP/E TTM
Latest Earnings
10-K
FY FY2025Mar 2, 202610-K for FY2025 was filed on 2026-03-03. AI summary is not available yet.
What Changed Recently
Fundamentals
How The Business Makes Money
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
Industry Biotechnology
Company Profile
CIK0001534133
ISINUS38942Q2021
CUSIP38942Q202
Phone858-952-5500
Address505 Coast Boulevard South, La Jolla, CA, 92037, US
SEC EDGAR